25 publications
Name | Date | Type | Actions |
---|---|---|---|
2016 sales: €350.3 million 4.3% like-for-like growth The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%. |
Public releases | ||
Q3 2011 Sales Vétoquinol achieved Q3 2011 sales of €68.4 million, in line with the previous year. |
Public releases | ||
Jacques du Puy appointed Vétoquinol Managing Director Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment |
Public releases | ||
Forcyl®: european launch of new drug Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection. |
Public releases | ||
Rapport financier semestriel 2011 (french) > Rapport d’activité semestriel 2011 |
Half Year Report | ||
2011 Half Year Results 2011 Half year results |
Half Year Report | ||
Vétoquinol continues to develop its product ranges and enters the brazilian market Lure (France), August 30, 2011 – The Vetoquinol Board Meeting of August 29, 2011 reviewed the Group’s business and approved the financial statements for the first half 2011. |
Public releases | ||
International expansion and new product launches Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011. |
Public releases | ||
European launch of new Nsaid Cimalgex® Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs. |
Public releases | ||
VÉTOQUINOL enters the brazilian Market Lure (France), June 7, 2011 – Vetoquinol announces the acquisition of 100% of the equity of Farmagricola SA in Brazil. |
Public releases |